Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 33

Results For "non"

1706 News Found

Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore
News | March 14, 2026

Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore

Remidex manufactures micronutrient premixes and nutraceuticals,


WHO Foundation and Novo Nordisk join hands to fight childhood obesity in India
News | March 14, 2026

WHO Foundation and Novo Nordisk join hands to fight childhood obesity in India

The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems


Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
News | March 12, 2026

Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio

The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth


FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
Medical Device | March 12, 2026

FDA nod to LifeVac De Novo, paving for next-generation anti-choking device

The FDA classified LifeVac as a Class II medical device


Roche shareholders back full slate of proposals, approve record dividend increase
News | March 11, 2026

Roche shareholders back full slate of proposals, approve record dividend increase

Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes


Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
News | March 10, 2026

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications


Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer
Biotech | March 10, 2026

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients